Programm
08:00 - 09:00 | Arrival of participants | Welcome coffee, registration |
09:00 - 09:15 | Welcome note | Prof. Dr. Dirk Wilhelm, Dean and Managing Director ZHAW School of Engineering Video |
09:15 - 09:40 | Keynote 1 | Digital Health – a vision comes to life Prof. Dr. Sven Hirsch, Director ZHAW Digital Health Lab |
09:40 - 10:05 | Keynote 2 | Programme DigiSanté – Management Update Gian-Reto Grond, Bundesamt für Gesundheit BAG |
10:05 - 10:30 | Keynote 3 | Bridging Lived Experience and Innovation in Rehabilitation Robotics Prof. Dr. Roger Gassert, ETH Zürich, Departement Gesundheitswissenschaften und Technologie |
10:30 - 11:00 | Break | Coffee break, sponsor exhibition and networking |
11:00 - 12:00 | Startup-Pitches | Presenter: Dr. Christian Russ, ZHAW, Head of research area Digital Business Leaders |
12:00 - 12:30 | Poster exhibition | |
12:30 - 13:30 | Lunch break | Lunch, sponsor exhibition and networking |
13:30 - 15:00 | Workshops | According to separate program, see: Workshops |
15:00 - 15:30 | Break | Coffee break, sponsor exhibition and networking |
15:30 - 15:55 | Keynote 4 | The role of digital biomarkers in evidence generation – development, use and value Dr. Guy Bogaarts, Digital Biomarkers Solutions Manager, Roche Diagnostics |
15:55 - 16:15 | DHL-Start-up Award | Presenter: Dr. Christian Russ, ZHAW, Head of research area Digital Business Leaders Video |
16:15 - 16:45 | Panel discussion | Moderated stage discussion with guests |
16:45 - 17:00 | Wrap-up | Closing remarks |
17:00 - 19:00 | Networking Apero | Apéro, networking and socializing |
Keynote Abstracts
Keynote 1 | Digital Health – a vision comes to life Prof. Dr. Sven Hirsch, Director ZHAW Digital Health Lab Digital Health has progressed significantly, impacting various aspects of healthcare. The keynote will demonstrate how the ZHAW Digital Health Lab is leveraging these advancements in its projects. The digital twin concept, which is a virtual representation that serves as the real-time digital counterpart of a physical object or process, picks up attention in healthcare. The presentation will highlight the practical applications and potential benefits of these developments for healthcare innovation. |
Keynote 2 | Programm DigiSanté – Stand der Dinge Gian-Reto Grond, Bundesamt für Gesundheit BAG
|
Keynote 3 | Bridging Lived Experience and Innovation in Rehabilitation Robotics Prof. Dr. Roger Gassert, ETH Zurich, Department of Health Sciences and Technology Robot-assisted sensorimotor therapy following neurological injury holds significant potential to enhance conventional approaches by enabling earlier, more varied, and intensive treatment. This approach can alleviate the workload on therapists and provide sophisticated assessments through integrated measures. Despite these advantages, the robotic systems currently used in clinical settings are often complex and difficult to use, necessitating trained therapists for setup and supervision, which limits their overall impact. Drawing on my experiences as both a researcher and a patient who underwent seven months of intensive neurorehabilitation, I will discuss these challenges. I will also highlight our efforts to fully realize the benefits of robot-assisted therapy across the continuum of care, aiming to substantially increase the therapy dose available to patients. |
Keynote 4 | The role of digital biomarkers in evidence generation – development, use and value Dr. Guy Bogaarts, Digital Biomarkers Solutions Manager, Roche Diagnostics Before a new drug can be released on the market, pharmaceutical companies have to run clinical trials to provide evidence that the drug leads to an improvement in how patients feel, function, or survive. This is typically assessed by biomarkers and clinical outcome assessments collected infrequently during hospital visits. Over the last decade, Roche has pioneered the development of novel ways of measuring biomarkers and clinical outcomes using smart-phones and -watches. These so-called digital biomarkers may provide more objective, sensitive, real-world measures of disease progression which may ultimately lead to shorter and smaller trials. However, before these new digital biomarkers can be widely used and accepted by health authorities, we also need to provide evidence that the technology we use is fit for purpose, that we measure accurately what we claim we measure, and that what we measure is clinically relevant. We at Roche are currently working on this evidence generation and making our internally developed digital biomarkers available to other pharmaceutical companies and research institutions. |